Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink

被引:72
作者
Landis, Sarah H. [1 ]
Suruki, Robert [2 ]
Hilton, Emma [3 ]
Compton, Chris [3 ]
Galwey, Nicholas W. [4 ]
机构
[1] GlaxoSmithKline, Real World Evidence, London, England
[2] GlaxoSmithKline, Real World Evidence, Res Triangle Pk, NC USA
[3] GlaxoSmithKline, Resp Med Franchise, Uxbridge, Middx, England
[4] GlaxoSmithKline, Target Sci Stat, Stevenage, Herts, England
关键词
Biomarker stability; blood eosinophils; COPD; primary care; OBSTRUCTIVE PULMONARY-DISEASE; INDUCED SPUTUM; EXACERBATIONS; MARKERS; REPEATABILITY; VARIABILITY; BIOMARKER; OUTCOMES; ASTHMA; TRIAL;
D O I
10.1080/15412555.2017.1313827
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
100201 [内科学];
摘要
Blood eosinophil counts may be predictive of corticosteroid response in chronic obstructive pulmonary disease (COPD) patients. However, little is known about measurement stability, which is important for understanding the utility of blood eosinophil counts as a potential biomarker. We evaluated the stability of blood eosinophil counts over 1 year in a population-based cohort of patients with COPD in primary care. Patients were aged >= 40 years with forced expiratory volume in 1 second/forced vital capacity < 0.7 and >= 1 blood eosinophil measurement taken during a period of stable disease within 6 months of a COPD diagnosis code recorded between January 1, 2010 and December 31, 2012. Generalized linear mixed models were fitted to log-transformed data to estimate the between-(s(between)(2)) and within-patient (s(within)(2)) variance in eosinophil count; an intra-class correlation coefficient R-i was calculated (s(between)(2)/[s(between)(2) + s(within)(2)]). A sensitivity analysis was performed from which patients who were prescribed systemic corticosteroids or antibiotics at any time during follow-up were excluded. All models were adjusted for age, gender, smoking status, and asthma history. Overall, 27,557 patients were included in the full cohort (51.5% male, mean age [standard deviation] 71.1 [10.6] years) and 54% of patients had 2 eosinophil measurements (median >= 2 [interquartile range 1]) during follow-up. For the full cohort, R-i = 0.64, and in the sensitivity analysis subgroup,R-i = 0.70, mainly due to a decrease in s(within)(2). For patients with COPD in primary care, eosinophil measurements demonstrated reasonable repeatability over 1 year, which increased after exclusion of patients who were prescribed systemic corticosteroids or antibiotics.
引用
收藏
页码:382 / 388
页数:7
相关论文
共 24 条
[1]
Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability [J].
Alexander, Kristine S. ;
Kazmierczak, Steven C. ;
Snyder, Caryn K. ;
Oberdorf, Jon A. ;
Farrell, David H. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) :1875-1882
[2]
Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial [J].
Bafadhel, Mona ;
McKenna, Susan ;
Terry, Sarah ;
Mistry, Vijay ;
Pancholi, Mitesh ;
Venge, Per ;
Lomas, David A. ;
Barer, Michael R. ;
Johnston, Sebastian L. ;
Pavord, Ian D. ;
Brightling, Christopher E. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (01) :48-55
[3]
Eosinophilic inflammation in stable chronic obstructive pulmonary disease - Relationship with neutrophils and airway function [J].
Balzano, G ;
Stefanelli, F ;
Iorio, C ;
De Felice, A ;
Melillo, EM ;
Martucci, M ;
Melillo, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (05) :1486-1492
[4]
Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD [J].
Beeh, KM ;
Beier, J ;
Kornmann, O ;
Mander, A ;
Buhl, R .
CHEST, 2003, 123 (03) :778-783
[5]
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease [J].
Bestall, JC ;
Paul, EA ;
Garrod, R ;
Garnham, R ;
Jones, PW ;
Wedzicha, JA .
THORAX, 1999, 54 (07) :581-586
[6]
Boorsma Martin, 2007, COPD, V4, P321, DOI 10.1080/15412550701597720
[7]
Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability [J].
Brightling, CE ;
Monterio, W ;
Green, RH ;
Parker, D ;
Morgan, MDL ;
Wardlaw, AJ ;
Pavord, ID .
RESPIRATORY MEDICINE, 2001, 95 (12) :999-1002
[8]
Fleiss J., 1986, Reliability of measurement: the design and analysis of clinical experiments
[9]
Outcomes and markers in the assessment of chronic obstructive pulmonary disease [J].
Jones, PW ;
Agusti, AGN .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (04) :822-832
[10]
Katz Lynn E, 2014, Ann Am Thorac Soc, V11, P531, DOI 10.1513/AnnalsATS.201310-354OC